Literature DB >> 29305288

Clinical Outcomes, Return to Sports, and Patient Satisfaction After Anterior Cruciate Ligament Reconstruction in Young and Middle-Aged Patients in an Asian Population-A 2-Year Follow-up Study.

Kae Sian Tay1, Andrew Hwee Chye Tan2.   

Abstract

PURPOSE: To compare the clinical outcomes of arthroscopic anterior cruciate ligament (ACL) reconstruction in young and middle-aged Asians.
METHODS: A retrospective study was performed using prospectively collected data from a tertiary institution ACL registry. All Asian patients with ACL tears who underwent primary arthroscopic ACL reconstruction by a single surgeon between 2008 and 2014, with minimum 2-year follow-up, were included. Patients with previous knee surgery or multiligamentous knee injuries were excluded. Two groups were formed: young patients (YP) (age <30) and middle-aged patients (MP) (age >40). They were compared preoperatively and 6 months, 1 year, and 2 years postoperatively for demographics, knee range of motion, anterior laxity, Tegner level, Lysholm and International Knee Documentation Committee grade, ability to return to preinjury level of activity, and patient satisfaction.
RESULTS: YP (n = 84) and MP (n = 22) had differences in mean age (YP = 23.1 years, range 18-29 years; MP = 46.4 years, range 41-59 years, P < .001), preinjury Tegner level (YP = 7.4, MP = 6.4, P = .005), and preoperative Lysholm scores (YP = 65.3, MP = 53.0, P = .034). The incidence of meniscal and chondral injuries was similar. Two years postoperatively, both groups had comparable knee range of motion and anterior laxity. The Tegner score was different (YP = 6.3, MP = 5.2, P = .028), but the proportion of patients returning to preinjury Tegner level (YP = 45.2%, MP = 46.9%, P = .812), Lysholm scores (YP = 92.5, MP = 93.8, P = .794), proportion of patients with knees rated International Knee Documentation Committee A/B (YP = 77.4%, MP = 81.8%, P = .777), and satisfaction levels (YP = 98.5%, MP = 94.1%, P = .370) were similar. There were no graft ruptures or reoperations.
CONCLUSIONS: In an Asian, predominantly male population, the clinical outcomes of arthroscopic ACL reconstruction in YP and MP are equally good at 2-year follow-up. MP can benefit as much as younger patients from ACL reconstruction in terms of restoration of knee function and return to preinjury activity level, are equally satisfied with outcomes, and should not be excluded from surgery on the basis of age alone. LEVEL OF EVIDENCE: Level III, retrospective comparative study.
Copyright © 2017 Arthroscopy Association of North America. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 29305288     DOI: 10.1016/j.arthro.2017.10.039

Source DB:  PubMed          Journal:  Arthroscopy        ISSN: 0749-8063            Impact factor:   4.772


  4 in total

1.  Outcomes of Anterior Cruciate Ligament Reconstruction in Patients Older Than 50 Years and Younger Than 30 Years.

Authors:  Chun-Jui Weng; Cheng-Pang Yang; Wen-Ling Yeh; Kuo-Yao Hsu; Shih-Sheng Chang; Chih-Hao Chiu; Alvin Chao-Yu Chen; Yi-Sheng Chan
Journal:  Orthop J Sports Med       Date:  2022-05-12

2.  Tegner level is predictive for successful return to sport 2 years after anterior cruciate ligament reconstruction.

Authors:  Antonio Klasan; Sven Edward Putnis; Samuel Grasso; Vikram Kandhari; Takeshi Oshima; David Anthony Parker
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2020-10-28       Impact factor: 4.114

Review 3.  Effects of Platelet-Rich Plasma on Clinical Outcomes After Anterior Cruciate Ligament Reconstruction: A Systematic Review and Meta-analysis.

Authors:  Ting Zhu; Jingbin Zhou; Jooyeon Hwang; Xin Xu
Journal:  Orthop J Sports Med       Date:  2022-01-31

4.  Quadriceps and hamstring tendon autografts in ACL reconstruction yield comparably good results in a prospective, randomized controlled trial.

Authors:  Hauke Horstmann; Maximilian Petri; Uwe Tegtbur; Gernot Felmet; Christian Krettek; Michael Jagodzinski
Journal:  Arch Orthop Trauma Surg       Date:  2021-03-19       Impact factor: 3.067

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.